These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 17166802)

  • 21. A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease.
    Zhang RY; Leon AC; Chuang-Stein C; Romano SJ
    Clin Trials; 2011 Feb; 8(1):5-14. PubMed ID: 21335586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint.
    Mani RB
    Stat Med; 2004 Jan; 23(2):305-14. PubMed ID: 14716731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Research and standardization in Alzheimer's trials: reaching international consensus.
    Carrillo MC; Rowe CC; Szoeke C; Masters CL; Ames D; O'Meara T; Macaulay SL; Milner A; Ellis KA; Maruff P; Rainey-Smith SR; Martins RN; Bain LJ; Head RJ;
    Alzheimers Dement; 2013 Mar; 9(2):160-8. PubMed ID: 23266004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AddNeuroMed--the European collaboration for the discovery of novel biomarkers for Alzheimer's disease.
    Lovestone S; Francis P; Kloszewska I; Mecocci P; Simmons A; Soininen H; Spenger C; Tsolaki M; Vellas B; Wahlund LO; Ward M;
    Ann N Y Acad Sci; 2009 Oct; 1180():36-46. PubMed ID: 19906259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controversies in Alzheimer's disease drug development.
    Cummings JL
    Int Rev Psychiatry; 2008 Aug; 20(4):389-95. PubMed ID: 18925488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular PET imaging in multicenter Alzheimer's therapeutic trials: current trends and implementation strategies.
    Seibyl J; Zubal IG; Jennings D; Marek K; Doraiswamy PM
    Expert Rev Neurother; 2011 Dec; 11(12):1783-93. PubMed ID: 22091601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Noncholinergic treatment options for Alzheimer's disease.
    Sano M
    J Clin Psychiatry; 2003; 64 Suppl 9():23-8. PubMed ID: 12934971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disease modifying trials in Alzheimer's disease: perspectives for the future.
    Vellas B; Coley N; Andrieu S
    J Alzheimers Dis; 2008 Oct; 15(2):289-301. PubMed ID: 18953115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies.
    Cummings JL
    Rev Neurol Dis; 2007; 4(2):57-62. PubMed ID: 17609636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing health economic outcome in Alzheimer's disease clinical trials.
    Jonsson L
    J Nutr Health Aging; 2007; 11(4):353-5. PubMed ID: 17653498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials for Alzheimer's disease.
    Fillit H; Cummings J; Neumann P; McLaughlin T; Salavtore P; Leibman C
    J Nutr Health Aging; 2010 Oct; 14(8):640-7. PubMed ID: 20922340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New and emerging treatments for Alzheimer's disease.
    Corbett A; Ballard C
    Expert Opin Emerg Drugs; 2012 Jun; 17(2):147-56. PubMed ID: 22439621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden--regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials.
    Isaac M; Vamvakas S; Abadie E; Jonsson B; Gispen C; Pani L
    Eur Neuropsychopharmacol; 2011 Nov; 21(11):781-8. PubMed ID: 21903360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease.
    Wesnes K; Edgar C; Andreasen N; Annas P; Basun H; Lannfelt L; Zetterberg H; Blennow K; Minthon L
    Acta Neurol Scand; 2010 Oct; 122(4):270-7. PubMed ID: 20047570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials.
    Coley N; Andrieu S; Jaros M; Weiner M; Cedarbaum J; Vellas B
    Alzheimers Dement; 2011 Nov; 7(6):602-610.e2. PubMed ID: 21745761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What lessons can be learned from failed Alzheimer's disease trials?
    Toyn J
    Expert Rev Clin Pharmacol; 2015 May; 8(3):267-9. PubMed ID: 25860157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addressing the challenges of transforming laboratory advances into Alzheimer's Disease treatments.
    Karlawish JH; Clark CM
    Neurobiol Aging; 2002; 23(6):1043-9. PubMed ID: 12470801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. One Step Forward Toward a Surrogate Endpoint for Clinical Trials of Alzheimer's Disease Drugs: The Results of PharmaCog WP5 (European ADNI).
    Frisoni GB; Blin O; Bordet R
    J Alzheimers Dis; 2019; 69(1):1-2. PubMed ID: 30958385
    [No Abstract]   [Full Text] [Related]  

  • 39. Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force.
    Gauthier S; Alam J; Fillit H; Iwatsubo T; Liu-Seifert H; Sabbagh M; Salloway S; Sampaio C; Sims JR; Sperling B; Sperling R; Welsh-Bohmer KA; Touchon J; Vellas B; Aisen P
    J Prev Alzheimers Dis; 2019; 6(3):164-168. PubMed ID: 31062826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alzheimer's disease. Three-score years and then?
    Bryan J
    Health Serv J; 1998 Aug; 108(5619):suppl 4-5, 7-8. PubMed ID: 10185456
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.